Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustainability awareness among European dry eye disease specialists.

European journal of ophthalmology·2026
Same author

Neuroinflammation and mononuclear phagocytes in glaucoma: From ocular pathogenesis to central visual pathway involvement - A comprehensive review.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Long-Term Evolution of Treatment Outcomes with Once-Daily Ciclosporin A 0.1% Cationic Emulsion in Patients with Dry Eye Disease and Severe Keratitis.

Ophthalmology and therapy·2026
Same author

The combined use of in vivo confocal microscopy and optical coherence tomography in monitoring corneal infections.

Eye (London, England)·2026
Same author

Twelve-month outcomes after open bleb revision for Preserflo<sup>®</sup> microshunt bleb failure in refractory glaucoma patients.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Efficacy and Safety of the Preserflo<sup>®</sup> Microshunt as a Standalone Procedure Versus Its Combination with Phacoemulsification.

Journal of clinical medicine·2026
Same journal

Visual arrestin-1: how did we learn what we know today about this protein?

Progress in retinal and eye research·2026
Same journal

Transcending Genome-Wide Association Studies to Create Useful Multi-omic Views of Glaucoma.

Progress in retinal and eye research·2026
Same journal

Cutting-edge cross-linking biomaterials advancing ophthalmic therapeutics.

Progress in retinal and eye research·2026
Same journal

Scleral remodeling in myopia: mechanisms and therapeutic approaches.

Progress in retinal and eye research·2026
Same journal

Macular fibrosis secondary to neovascular age-related macular degeneration: from clinic to biology.

Progress in retinal and eye research·2026
Same journal

Stromal Transplantation and corneal-sparing techniques in ectatic diseases.

Progress in retinal and eye research·2026
See all related articles

Related Experiment Video

Updated: Feb 11, 2026

Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models
06:10

Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models

Published on: December 8, 2023

2.7K

Neurotrophic keratopathy.

Harminder S Dua1, Dalia G Said1, Elisabeth M Messmer2

  • 1Larry A Donoso Laboratory for Eye Research, Academic Section of Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Nottingham University Hospitals, NHS Trust, Nottingham, England, UK.

Progress in Retinal and Eye Research
|April 27, 2018
PubMed
Summary
This summary is machine-generated.

Neurotrophic keratitis (NK) impairs corneal sensation and healing, leading to vision loss. Recombinant nerve growth factor (cenegermin) offers a promising, targeted therapy for this condition.

Keywords:
KeratitisMatrix regenerating agentsNerve growth factorNeurotrophic keratopathyTrigeminal neve diseases

More Related Videos

Experimental Methods for Testing the Effects of Neurotrophic Peptide, ADNF-9, Against Alcohol-induced Apoptosis during Pregnancy in C57BL/6 Mice
09:50

Experimental Methods for Testing the Effects of Neurotrophic Peptide, ADNF-9, Against Alcohol-induced Apoptosis during Pregnancy in C57BL/6 Mice

Published on: April 24, 2013

12.2K
Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
11:13

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells

Published on: April 7, 2016

9.6K

Related Experiment Videos

Last Updated: Feb 11, 2026

Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models
06:10

Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models

Published on: December 8, 2023

2.7K
Experimental Methods for Testing the Effects of Neurotrophic Peptide, ADNF-9, Against Alcohol-induced Apoptosis during Pregnancy in C57BL/6 Mice
09:50

Experimental Methods for Testing the Effects of Neurotrophic Peptide, ADNF-9, Against Alcohol-induced Apoptosis during Pregnancy in C57BL/6 Mice

Published on: April 24, 2013

12.2K
Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
11:13

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells

Published on: April 7, 2016

9.6K

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Regenerative Medicine

Background:

  • Neurotrophic keratitis (NK) is characterized by corneal epitheliopathy and reduced sensation.
  • Impaired corneal nerves disrupt trophic support, leading to epithelial defects and potential stromal melting.
  • NK significantly impacts vision and quality of life, with current treatments offering limited, non-specific relief.

Purpose of the Study:

  • To review the pathophysiology of neurotrophic keratitis.
  • To discuss current and emerging therapeutic strategies for NK.
  • To highlight the potential of recombinant nerve growth factor (cenegermin) as a specific treatment.

Main Methods:

  • Literature review of neurotrophic keratitis.
  • Analysis of current medical and surgical interventions.
  • Evaluation of novel biological agents and recombinant nerve growth factor.

Main Results:

  • NK severity ranges from mild epithelial changes to severe stromal melting and perforation.
  • Existing treatments provide non-specific relief and carry risks.
  • Novel therapies, including biopolymers and cenegermin, show promise for addressing the underlying nerve pathology.

Conclusions:

  • Neurotrophic keratitis requires targeted therapies addressing nerve dysfunction.
  • Recombinant nerve growth factor (cenegermin) represents a significant advancement, offering specific treatment for NK.
  • Cenegermin has the potential to become a definitive therapy for neurotrophic keratitis.